| Not Yet Recruiting | A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS Extensive Stage Lung Small Cell Cancer | Phase 2 | 2026-05-01 |
| Recruiting | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Non-Small Cell Lung Cancer | Phase 3 | 2026-01-12 |
| Withdrawn | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | 2025-03-01 |
| Recruiting | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients Wi Non Small Cell Lung Cancer | Phase 3 | 2025-01-15 |
| Withdrawn | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer NSCLC, Stage III, ALK-rearrangement | Phase 2 | 2024-06-07 |
| Completed | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal P Breast Cancer | Phase 2 | 2024-01-23 |
| Recruiting | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC SCLC,Extensive Stage, SLFN11-positive | Phase 2 | 2023-12-20 |
| Active Not Recruiting | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status NSCLC Stage IV, KRAS P.G12C | Phase 2 | 2023-06-12 |
| Active Not Recruiting | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Non Small Cell Lung Cancer | Phase 2 | 2023-03-27 |
| Recruiting | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases Non-Small Cell Lung Cancer, Melanoma | Phase 3 | 2022-11-30 |
| Terminated | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | 2022-08-04 |
| Completed | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | Phase 2 | 2020-09-29 |
| Active Not Recruiting | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC Non-small Cell Lung Cancer, Stage IV, Oligometastasis | Phase 2 | 2019-11-19 |
| Active Not Recruiting | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Breast Cancer Recurrent | Phase 3 | 2019-08-27 |
| Completed | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Pleural Mesothelioma Malignant Advanced | Phase 3 | 2019-04-30 |
| Completed | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer | Phase 2 | 2019-04-16 |
| Terminated | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent | Phase 2 | 2018-11-06 |
| Completed | MEtronomic TrEatment Option in Advanced bReast cAncer Breast Cancer | Phase 2 | 2017-09-13 |
| Completed | PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelio Pleural Mesothelioma Malignant Advanced | Phase 3 | 2017-09-12 |
| Completed | Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Con Non Small Cell Lung Cancer Metastatic | Phase 2 | 2017-05-31 |
| Completed | Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2016-08-30 |
| Completed | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | 2015-12-18 |
| Completed | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-small Cell Lung Cancer Stage III | Phase 2 | 2015-11-25 |
| Completed | Afatinib in NSCLC With HER2 Mutation NSCLC | Phase 2 | 2015-09-16 |
| Terminated | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Lung Cancer Non-small Cell Stage IV | Phase 3 | 2015-01-06 |
| Active Not Recruiting | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer Early Breast Cancer | N/A | 2014-12-04 |
| Completed | Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer Metastatic Breast Cancer | Phase 1 / Phase 2 | 2014-12-01 |
| Completed | TRial on the Endocrine Activity of Neoadjuvant Degarelix Breast Cancer Invasive Nos | Phase 2 | 2014-02-01 |
| Completed | Schedules of Nab-Paclitaxel in Metastatic Breast Cancer Metastatic Breastcancer | Phase 2 | 2013-04-01 |
| Completed | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using Veri Carcinoma, Non-Small-Cell Lung | Phase 3 | 2012-08-01 |
| Completed | BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) Lung Cancer | Phase 2 | 2012-06-01 |
| Completed | Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years o Breast Cancer | — | 2011-01-01 |
| Completed | Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane Breast Cancer, Osteoporosis | N/A | 2009-08-03 |
| Completed | Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Breast Cancer | N/A | 2008-11-25 |
| Completed | Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Ear Breast Cancer, Fatigue, Sleep Disorders | Phase 3 | 2007-12-01 |
| Completed | Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Horm Breast Cancer | Phase 3 | 2007-08-01 |
| Terminated | Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women W Breast Cancer | Phase 3 | 2005-08-01 |
| Terminated | Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Breast Cancer, Osteoporosis | Phase 3 | 2005-04-01 |
| Completed | Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCS Breast Cancer, Cognitive/Functional Effects, Fatigue | Phase 3 | 2005-04-01 |
| Completed | Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IB Breast Cancer, Osteoporosis | Phase 3 | 2004-05-01 |
| Completed | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma | Phase 3 | 2003-12-17 |
| Completed | Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Breast Cancer | Phase 3 | 2003-11-03 |
| Terminated | Premenopausal Endocrine Responsive Chemotherapy Trial Breast Cancer | Phase 3 | 2003-08-01 |
| Withdrawn | Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Breast Cancer, Osteoporosis | Phase 3 | 2003-02-01 |
| Completed | Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy Breast Cancer | Phase 3 | 2002-07-01 |
| Terminated | IBCSG Trial 22-00 Serum Substudy Breast Cancer | N/A | 2002-06-01 |
| Completed | Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Breast Cancer | N/A | 2001-12-01 |
| Completed | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Breast Cancer | Phase 3 | 2000-11-01 |
| Completed | Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Breast Cancer | Phase 3 | 1998-03-01 |
| Completed | High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combinatio Breast Cancer | Phase 3 | 1996-06-01 |
| Completed | Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Breast Cancer | Phase 3 | 1993-05-01 |
| Completed | Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer Breast Cancer | Phase 3 | 1993-05-01 |